ES2086270T5 - Metabolitos de terfenadina y sus isomeros opticamente puros para tratar trastornos alergicos. - Google Patents

Metabolitos de terfenadina y sus isomeros opticamente puros para tratar trastornos alergicos.

Info

Publication number
ES2086270T5
ES2086270T5 ES93918584T ES93918584T ES2086270T5 ES 2086270 T5 ES2086270 T5 ES 2086270T5 ES 93918584 T ES93918584 T ES 93918584T ES 93918584 T ES93918584 T ES 93918584T ES 2086270 T5 ES2086270 T5 ES 2086270T5
Authority
ES
Spain
Prior art keywords
terfenadine
metabolites
optically pure
allergic disorders
pure isomers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93918584T
Other languages
English (en)
Other versions
ES2086270T1 (es
ES2086270T3 (es
Inventor
James W Young
Nancy M Gray
Raymond L Woosley
Yiwang Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma America Inc
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27129882&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2086270(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sepracor Inc filed Critical Sepracor Inc
Publication of ES2086270T1 publication Critical patent/ES2086270T1/es
Application granted granted Critical
Publication of ES2086270T3 publication Critical patent/ES2086270T3/es
Publication of ES2086270T5 publication Critical patent/ES2086270T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Epoxy Compounds (AREA)

Abstract

UNA COMPOSICION FARMACEUTICA QUE COMPRENDE UN COMPUESTO DE FORMULA (I): DONDE Z ES COOH, COOCH{SUB,3} O CH{SUB,2}OH, O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO, PARA USAR EN UN TRATAMIENTO ANTIHISTAMINICO QUE NO INDUZCA UNA ARRITMIA CARDIACA SIGNIFICATIVA, QUE CONSTA DE LA ADMINISTRACION DE UNA CANTIDAD TERAPEUTICAMENTE EFICAZ DE UN COMPUESTO DE FORMULA (I) A UN PACIENTE HUMANO.
ES93918584T 1992-08-03 1993-08-03 Metabolitos de terfenadina y sus isomeros opticamente puros para tratar trastornos alergicos. Expired - Lifetime ES2086270T5 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92418292A 1992-08-03 1992-08-03
US92415692A 1992-08-03 1992-08-03

Publications (3)

Publication Number Publication Date
ES2086270T1 ES2086270T1 (es) 1996-07-01
ES2086270T3 ES2086270T3 (es) 1998-03-01
ES2086270T5 true ES2086270T5 (es) 2001-02-01

Family

ID=27129882

Family Applications (3)

Application Number Title Priority Date Filing Date
ES97104837T Expired - Lifetime ES2257757T3 (es) 1992-08-03 1993-08-03 Carboxilato de terfenadina y el tratamiento de trastornos alergicos.
ES02006356T Expired - Lifetime ES2284740T3 (es) 1992-08-03 1993-08-03 Carboxilato de terfenadina y el tratamiento de la irritacion cutanea.
ES93918584T Expired - Lifetime ES2086270T5 (es) 1992-08-03 1993-08-03 Metabolitos de terfenadina y sus isomeros opticamente puros para tratar trastornos alergicos.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ES97104837T Expired - Lifetime ES2257757T3 (es) 1992-08-03 1993-08-03 Carboxilato de terfenadina y el tratamiento de trastornos alergicos.
ES02006356T Expired - Lifetime ES2284740T3 (es) 1992-08-03 1993-08-03 Carboxilato de terfenadina y el tratamiento de la irritacion cutanea.

Country Status (24)

Country Link
US (1) US5375693A (es)
EP (4) EP0815860B1 (es)
JP (6) JP3041954B2 (es)
KR (1) KR950702420A (es)
AT (3) ATE162399T1 (es)
AU (3) AU675240B2 (es)
BR (1) BR9306841A (es)
CA (1) CA2141572C (es)
CZ (1) CZ27495A3 (es)
DE (5) DE9320925U1 (es)
DK (3) DK0815860T3 (es)
ES (3) ES2257757T3 (es)
FI (1) FI950467L (es)
GB (1) GB2284351B (es)
GR (3) GR960300024T1 (es)
HK (1) HK1045806B (es)
HU (1) HU226242B1 (es)
NO (1) NO310644B1 (es)
PL (1) PL174373B1 (es)
PT (2) PT815860E (es)
RO (1) RO116043B1 (es)
RU (1) RU2167657C2 (es)
SK (1) SK12495A3 (es)
WO (1) WO1994003170A1 (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU223774B1 (hu) * 1992-05-11 2005-01-28 Merrell Dow Pharmaceuticals Inc. Terfenadinszármazékok alkalmazása antihisztamin hatású gyógyszerkészítmények előállítására
DE9320925U1 (de) 1992-08-03 1995-08-31 Georgetown University, Washington, D.C. Terfenadin-Metabolite und deren optisch reine Isomere für die Behandlung von allergischen Störungen
US20020007068A1 (en) 1999-07-16 2002-01-17 D'ambra Thomas E. Piperidine derivatives and process for their production
EP0703902B1 (en) * 1993-06-24 1998-12-16 Albany Molecular Research, Inc. Process for the production of piperidine derivatives
WO1995010278A1 (en) * 1993-10-15 1995-04-20 Hoechst Marion Roussel, Inc. Treatment of allergic disorders with terfenadine carboxylate
US20030045722A1 (en) * 1994-05-18 2003-03-06 Henton Daniel R. Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof
CN1148849A (zh) * 1994-05-18 1997-04-30 赫彻斯特马里恩鲁斯公司 抗组胺哌啶衍生物，其多晶形物和假同晶物的无水和水合物形式的制备方法
US5455049A (en) * 1995-01-04 1995-10-03 Ascent Pharmaceuticals, Inc. Terfenadine oral powder
WO1996026726A1 (en) * 1995-02-28 1996-09-06 Hoechst Marion Roussel, Inc. Pharmaceutical composition for piperidinoalkanol compounds
GB9513972D0 (en) * 1995-07-08 1995-09-06 Merck Sharp & Dohme Pharmaceutical compositions
US5906747A (en) * 1995-11-13 1999-05-25 Biosepra Inc. Separation of molecules from dilute solutions using composite chromatography media having high dynamic sorptive capacity at high flow rates
US5908850A (en) * 1995-12-04 1999-06-01 Celgene Corporation Method of treating attention deficit disorders with d-threo methylphenidate
US5837284A (en) * 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US6486177B2 (en) * 1995-12-04 2002-11-26 Celgene Corporation Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
US6355656B1 (en) 1995-12-04 2002-03-12 Celgene Corporation Phenidate drug formulations having diminished abuse potential
US5922736A (en) * 1995-12-04 1999-07-13 Celegene Corporation Chronic, bolus administration of D-threo methylphenidate
US5733756A (en) * 1996-01-05 1998-03-31 Celgene Corporation Lactams and processes for stereoselective enrichment of lactams, amides, and esters
US6201124B1 (en) 1995-12-21 2001-03-13 Albany Molecular Research, Inc. Process for production of piperidine derivatives
US6153754A (en) * 1995-12-21 2000-11-28 Albany Molecular Research, Inc. Process for production of piperidine derivatives
ES2124167B1 (es) * 1996-06-04 1999-09-16 Espanola Prod Quimicos Nuevos derivados del bencimidazol con actividad antihistaminica.
US5925761A (en) * 1997-02-04 1999-07-20 Sepracor Inc. Synthesis of terfenadine and derivatives
US6962997B1 (en) * 1997-05-22 2005-11-08 Celgene Corporation Process and intermediates for resolving piperidyl acetamide steroisomers
CN1159012C (zh) * 1997-08-26 2004-07-28 阿旺蒂斯制药公司 用于组合哌啶子基烷醇-减充血剂的药物组合物
US6194431B1 (en) 1998-04-14 2001-02-27 Paul D. Rubin Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors
DE19913862C2 (de) * 1999-03-26 2003-04-10 Forschungszentrum Juelich Gmbh Verfahren zur biokatalysierten Umsetzung schlecht wasserlöslicher Substanzen
DE10007203A1 (de) * 2000-02-17 2001-08-23 Asta Medica Ag Neue Kombination nichtsedierender Antihistaminika mit Substanzen, die die Leukotrienwirkung beeinflussen, zur Behandlung der Rhinitis/Konjunktivitis
US6613907B2 (en) 2000-11-08 2003-09-02 Amr Technology, Inc. Process for the production of piperidine derivatives with microorganisms
CZ20033019A3 (cs) * 2001-04-09 2004-07-14 Teva Pharmaceutical Industries Ltd. Polymorfní formy chloridu fexofenadinu
US20030021849A1 (en) * 2001-04-09 2003-01-30 Ben-Zion Dolitzky Polymorphs of fexofenadine hydrochloride
BR0117054A (pt) * 2001-06-18 2004-07-27 Reddys Lab Ltd Dr Formas cristalinas do ácido 4-[4-[4-hidroxidifenilmetil)-1-piperidinil]-1-hidroxibuti l]-alfa, alfa-dimetilbenzeno acético e seu cloridrato
WO2003020274A1 (en) * 2001-08-30 2003-03-13 Aventis Pharmaceuticals Inc. Treatment of atopic dermatitis
ES2239554T1 (es) * 2002-06-10 2005-10-01 Teva Pharmaceutical Industries Ltd. Forma xvi polimorfica de hidrocloruro de fexofenadina.
TWI326214B (en) * 2002-07-17 2010-06-21 Avanir Pharmaceuticals Inc Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
RU2238081C1 (ru) * 2003-07-14 2004-10-20 Открытое акционерное общество "Московская фармацевтическая фабрика" Средство антиконгестивного действия
US20050026890A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an antihistamine for treatment of asthma or chronic obstructive pulmonary disease
TW200517114A (en) 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
JP4515121B2 (ja) 2004-03-15 2010-07-28 東芝テック株式会社 ワイヤドットプリンタヘッド及びワイヤドットプリンタ
JP4473021B2 (ja) 2004-03-22 2010-06-02 東芝テック株式会社 窒化層形成方法、磁気回路形成部材、アーマチュア、ワイヤドットプリンタヘッド及びワイヤドットプリンタ
US20050239830A1 (en) * 2004-04-26 2005-10-27 Vikram Khetani Methods of diminishing co-abuse potential
US20050256163A1 (en) * 2004-04-26 2005-11-17 Ilan Kor Crystalline forms of fexofenadine hydrochloride and processes for their preparation
US7498345B2 (en) 2004-09-17 2009-03-03 Albany Molecular Research, Inc. Process for production of piperidine derivatives
US7498443B2 (en) 2004-09-17 2009-03-03 Albany Molecular Research, Inc. Process for production of carebastine
JP2008514641A (ja) * 2004-09-28 2008-05-08 テバ ファーマシューティカル インダストリーズ リミティド 結晶形フェキソフェナジン、およびその調製方法
CA2591247A1 (en) * 2004-12-09 2006-06-15 Celgene Corporation Treatment of patients suffering from a disease having a family history or diagnosis of tics or tourette's syndrome with d-threo methylphenidate
WO2007056457A2 (en) 2005-11-09 2007-05-18 Combinatorx, Incorporated Methods, compositions, and kits for the treatment of medical conditions
EP2420238A3 (en) * 2007-04-13 2012-03-07 Southern Research Institute Anti-angiogenic agents
US20090076080A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched fexofenadine
US20150238473A1 (en) * 2012-09-27 2015-08-27 University Of Rochester Methods and compositions for treating infection
US10420756B2 (en) * 2015-03-26 2019-09-24 Sen-Jam Pharmaceutical Llc. Methods and compositions to inhibit symptoms associated with veisalgia
DE102017130361A1 (de) 2017-12-18 2019-07-04 Lsp Innovative Automotive Systems Gmbh Statorzahn und Stator mit guter elektrischer Isolierung und gleichzeitig sehr hoher Wärmeleitfähigkeit zur Leistungssteigerung von Elektromotoren

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US880801A (en) † 1908-03-03 Harold Larsen Vibrator.
US922890A (en) † 1907-03-26 1909-05-25 Peder Joergen Hansen Stream-motor.
US4254129A (en) * 1979-04-10 1981-03-03 Richardson-Merrell Inc. Piperidine derivatives
US4552899A (en) † 1984-04-09 1985-11-12 Analgesic Associates Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs
US4829064A (en) † 1987-06-08 1989-05-09 Analgesic Associates Cough/cold mixtures comprising non-sedating antihistamine drugs
US4929605A (en) * 1987-10-07 1990-05-29 Merrell Dow Pharmaceuticals Inc. Pharmaceutical composition for piperidinoalkanol derivatives
US4996061A (en) † 1987-10-07 1991-02-26 Merrell Dow Pharmaceuticals Inc. Pharmaceutical composition for piperidinoalkanol-decongestant combination
ES2176201T3 (es) * 1992-04-10 2002-12-01 Merrell Pharma Inc Derivados de 4-difenilmetil piperidina y procedimiento de preparacion.
HU223774B1 (hu) 1992-05-11 2005-01-28 Merrell Dow Pharmaceuticals Inc. Terfenadinszármazékok alkalmazása antihisztamin hatású gyógyszerkészítmények előállítására
DE9320925U1 (de) * 1992-08-03 1995-08-31 Georgetown University, Washington, D.C. Terfenadin-Metabolite und deren optisch reine Isomere für die Behandlung von allergischen Störungen
EP0703902B1 (en) * 1993-06-24 1998-12-16 Albany Molecular Research, Inc. Process for the production of piperidine derivatives
JP3712208B2 (ja) * 1993-06-25 2005-11-02 メレルファーマスーティカルズ インコーポレイテッド 抗ヒスタミン性の４−ジフェニルメチル／ジフェニルメトキシピペリジン誘導体類を製造する新規な中間体
CA2128820A1 (en) * 1993-07-27 1995-01-28 Walter G. Gowan, Jr. Rapidly disintegrating pharmaceutical dosage form and process for preparation thereof
CA2128821A1 (en) * 1993-07-27 1995-01-28 Dilip J. Gole Freeze-dried pharmaceutical dosage form and process for separation thereof
WO1995010278A1 (en) * 1993-10-15 1995-04-20 Hoechst Marion Roussel, Inc. Treatment of allergic disorders with terfenadine carboxylate

Also Published As

Publication number Publication date
PT815860E (pt) 2006-08-31
JP2000086512A (ja) 2000-03-28
GB9502183D0 (en) 1995-03-22
DE69316660T3 (de) 2001-04-05
HK1045806B (en) 2008-03-14
ES2257757T3 (es) 2006-08-01
JP3288662B2 (ja) 2002-06-04
NO950374D0 (no) 1995-02-01
GR3026530T3 (en) 1998-07-31
DE69334008D1 (de) 2006-05-24
DK0701443T3 (da) 1998-02-09
EP0815860A2 (en) 1998-01-07
ATE363283T1 (de) 2007-06-15
JPH08500348A (ja) 1996-01-16
HK1045806A1 (en) 2002-12-13
RO116043B1 (ro) 2000-10-30
PT1214937E (pt) 2007-07-25
GR3035417T3 (en) 2001-05-31
GR960300024T1 (en) 1996-05-31
SK12495A3 (en) 1997-01-08
ES2284740T3 (es) 2007-11-16
DE9320925U1 (de) 1995-08-31
JP3288660B2 (ja) 2002-06-04
PL307339A1 (en) 1995-05-15
CA2141572A1 (en) 1994-02-17
CA2141572C (en) 2001-02-06
JP3288661B2 (ja) 2002-06-04
KR950702420A (ko) 1995-07-29
JP2000086515A (ja) 2000-03-28
DE69334145D1 (de) 2007-07-12
AU4798693A (en) 1994-03-03
JP3037697B2 (ja) 2000-04-24
FI950467A0 (fi) 1995-02-02
NO310644B1 (no) 2001-08-06
EP0701443B2 (en) 2000-11-22
CZ27495A3 (en) 1996-09-11
EP1214937A2 (en) 2002-06-19
DK0701443T4 (da) 2000-12-18
NO950374L (no) 1995-03-29
DK0815860T3 (da) 2006-08-14
GB2284351B (en) 1996-11-27
DE69334008T2 (de) 2006-10-19
AU7182296A (en) 1997-01-30
GB2284351A (en) 1995-06-07
JP3041954B2 (ja) 2000-05-15
ATE322899T1 (de) 2006-04-15
PL174373B1 (pl) 1998-07-31
BR9306841A (pt) 1998-12-08
HU226242B1 (en) 2008-07-28
US5375693A (en) 1994-12-27
FI950467A7 (fi) 1995-03-31
DK1214937T3 (da) 2007-09-17
DE69316660T2 (de) 1998-05-07
FI950467L (fi) 1995-03-31
AU675240B2 (en) 1997-01-30
EP0815860B1 (en) 2006-04-12
WO1994003170A1 (en) 1994-02-17
AU1842999A (en) 1999-04-29
JP2000086516A (ja) 2000-03-28
JP2000086514A (ja) 2000-03-28
JP2000086513A (ja) 2000-03-28
HU9500313D0 (en) 1995-03-28
EP0815860A3 (en) 1998-01-14
DE701443T1 (de) 1997-01-30
EP1214937B1 (en) 2007-05-30
DE69316660D1 (de) 1998-02-26
EP1214937A3 (en) 2002-10-30
HUT71889A (en) 1996-02-28
RU95107881A (ru) 1996-11-27
ATE162399T1 (de) 1998-02-15
EP1688142A1 (en) 2006-08-09
EP0701443B1 (en) 1998-01-21
ES2086270T1 (es) 1996-07-01
DE69334145T2 (de) 2008-01-24
RU2167657C2 (ru) 2001-05-27
ES2086270T3 (es) 1998-03-01
EP0701443A1 (en) 1996-03-20

Similar Documents

Publication Publication Date Title
ES2086270T5 (es) Metabolitos de terfenadina y sus isomeros opticamente puros para tratar trastornos alergicos.
ITMI911299A1 (it) Composizioni farmaceutiche attive nella terapia dei disturbi del sonno comprendenti melatonina o un suo derivato in associazione con un derivato benzodiazepinico
KR930702022A (ko) 인슐린의 경구 투여에 의한 타잎 1 당뇨병의 치료 또는 예방법
GB2285219A (en) Use of norastemizole for the treatment of allergic disorders
ES2136167T3 (es) Composiciones de idebenona para tratar la enfermedad de alzheimer.
ES2092646T3 (es) Metanoantracenos como antagonistas de dopamina.
ES2087623T3 (es) Derivados de bencimidazol como agente antimicrobiano contra campylobacter pylon.
ES2145902T3 (es) Aplicacion del riluzole en el tratamiento de las enfermedades mitocondriales.
CO4960654A1 (es) Metodo para el tratamiento de enfermedades fisiologicas relacionadas con el uso o con las secuelas provocadas por el uso de la cocaina u otros estimulantes psicomotores
ITRM920693A1 (it) Impiego di l-carnitina e acil l-carnitine nel trattamento di pazienti affetti da aids e sindromi correlate e di pazienti asintomatici hivsieropositivi.
NO923198L (no) Terapeutiske midler
MX9306005A (es) Combinaciones de ibupropeno-cafeina.
ES2101311T3 (es) Utilizacion de un dispositivo transdermico que contiene (e)-2-(p-fluorofenetil)-3-fluoroalilamina y su uso para el tratamiento de la enfermedad de alzheimer.
ES2073871T3 (es) Tiazolidin-2,4-dionas en el tratamiento de la hipertension.
MX9204711A (es) Compuestos terapeuticos.
MX9704887A (es) Composiciones farmaceuticas para el tratamiento de trastornos depresivos.
MX19761A (es) Nuevos compuestos y procedimiento para su obtencion.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 701443

Country of ref document: ES